Revolution Medicines, Inc. (FRA:42Z)

Germany flag Germany · Delayed Price · Currency is EUR
67.00
-2.00 (-2.90%)
At close: Nov 28, 2025
18.58%
Market Cap12.61B
Revenue (ttm)n/a
Net Income (ttm)-819.04M
Shares Outn/a
EPS (ttm)-4.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume8
Average Volume198
Open66.00
Previous Close69.00
Day's Range66.00 - 67.00
52-Week Range26.80 - 69.00
Betan/a
RSI75.32
Earnings DateFeb 26, 2026

About Revolution Medicines

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2014
Employees 534
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 42Z
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.